Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.

Yves Daniel CompaoreIssaka ZongoAnyirékun F SoméNouhoun BarryFrederick NikiémaTalato N KaboréAminata OuattaraZachari KabréKadidiatou WermiMoussa ZongoRakiswende S YerbangaIssaka SagaraAbdoulaye DjimdéJean Bosco Ouédraogo

Published in: Malaria journal (2021)

Pyronaridine-artesunate and artemether-lumefantrine showed similar hepatic safety when used repeatedly in participants with uncomplicated malaria. Pyronaridine-artesunate represents therefore a suitable alternative to the current first line anti-malarial drugs in use in endemic areas. Trial registration Pan African Clinical Trials Registry. PACTR201105000286876.

Keyphrases

plasmodium falciparum
clinical trial
urinary tract infection
phase ii
phase iii
study protocol
electronic health record
randomized controlled trial
machine learning
combination therapy
drug induced
double blind
smoking cessation
cone beam